Developing a machine-learning model to enable treatment selection for neoadjuvant chemotherapy for esophageal cancer
Neoadjuvant chemotherapy (NAC) with cisplatin plus 5-fluorouracil (CF) followed by radical surgery is the standard of care for stage II and III oesophageal cancer (EC) More potent regimens of CF plus docetaxel show an overall survival advantage over CF regimens but with worsening grade 3 or higher adverse events due to docetaxel. Based on these reports, the aim of this study was to develop a prognostic system for CF regimens, particularly for locally advanced cancer, to guide the choice of NAC. Furthermore, a comprehensive expression analysis was performed to understand the biological characteristics of the poor response group and to propose selective treatment for the poor response group.